GE Medical
This article was originally published in The Gray Sheet
Executive Summary
Shareholders of Madison, Wisconsin-based Lunar Corp. will receive 0.322 shares of GE stock for each share of Lunar stock under terms of the firms' merger deal completed Aug. 8. Announced June 2, the agreement was valued at roughly $144 mil. A manufacturer of diagnostics for osteoporosis and metabolic bone disease as well as orthopedic surgery devices, Lunar will add $91 mil. in annual revenues to GE's $7 bil. Medical Systems business. GEMS hopes to accelerate Lunar's top-line growth above the single-digit pace of the overall bone densitometry market (1"The Gray Sheet" June 5, p. 13)
You may also be interested in...
GEMS Shooting At Moon In Women's Health Via Lunar Densitometry Buy
GE Medical Systems is looking to expand its women's health business by applying its worldwide marketing resources to increase the reach of Lunar Corporation's densitometry and orthopedic imaging brands.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.